CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 45 enrolled
Drug / intervention
IBRUTINIB +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04273139
NCT04273139Phase 2Active
CompareCT.gov

Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia

Dana-Farber Cancer Institute·interventional·Posted Feb 17, 2020·Updated May 11, 2026

In Brief

A Phase 2 clinical trial evaluating IBRUTINIB and Venetoclax for Waldenstrom Macroglobulinemia and MYD88 Gene Mutation. Active but no longer recruiting, targeting 45 participants across 2 sites.

Detailed Summary

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: * Venetoclax * ibrutinib

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom Macroglobulinemia, MYD88 Gene Mutation
CountriesUnited States
CollaboratorsAbbVie, Pharmacyclics LLC.

Timeline

Phase 2Active
202020212022202320242025202620272028
First PostedFeb 17, 2020
Enrollment StartJul 9, 2020
Primary CompletionJun 6, 2022
Study CompletionFeb 1, 2028
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.4 years ago

Interventions

IBRUTINIBdrug

Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days

Venetoclaxdrug

Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.